文献速递妇科生殖医学

非典型增生及早期子宫内膜癌复发后再次保留生育功能治疗的疗效与妊娠结局

[Clinical efficacy and pregnancy outcomes of fertility-preserving re-treatment after recurrence of the patient with atypical endometrial hyperplasia and early stage endometrial carcinoma].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2020-01-01

该多中心回顾性研究分析了104例AEH和EEC患者中31例经初次保留生育治疗达完全缓解后复发病例,其中27例再次接受保留生育治疗,总体完全缓解率为81%(22/27),再复发率23%(5/22),有妊娠意愿者16例中12例妊娠、5例活产,中位随访73个月全部无瘤生存。

要点

  • 复发后再次保留生育治疗总体完全缓解率81%(22/27),AEH为13/16、EEC为9/11
  • 达完全缓解后再复发率23%(5/22),中位间隔33个月(21~80个月)
  • 有妊娠意愿者16例中12例妊娠(5例自然、7例辅助生殖),活产率5/12

核心结论

  • 经保留生育功能治疗达完全缓解后复发的AEH和EEC患者,在全面评估和充分知情同意下可再次选择保留生育功能治疗。
  • 再次治疗仍具有一定完全缓解率和妊娠率,但治疗期间须严密随访观察。

研究设计与样本

  • 多中心回顾性研究,收集2005年1月至2019年5月全国9家三级甲等医院收治的AEH和EEC患者共104例。
  • 整理其中经保留生育功能治疗达完全缓解后复发的31例患者(来自4家医院),27例再次接受保留生育功能治疗并进行分析。

主要发现

  • 27例再治疗患者中AEH 16例、EEC 11例,再治疗后22例达完全缓解,总体完全缓解率81%(22/27),AEH为13/16、EEC为9/11。
  • 22例达完全缓解者中5例再复发,再复发率23%(5/22),两次复发中位间隔33个月(范围21~80个月)。
  • 再复发5例中4例行全面分期手术,1例充分知情后选择第3轮保留生育治疗并于15个月后达完全缓解。
  • 有妊娠意愿者16例,12例妊娠(妊娠率12/16),其中自然妊娠5例、辅助生殖技术后妊娠7例,活产5例(活产率5/12)。
  • 随访截至2019年5月,中位随访73个月(范围0~123个月),27例再治疗患者均无瘤生存。

临床怎么用

  • 对初次保留生育治疗达完全缓解后复发的AEH和EEC患者,可在全面评估病情并充分知情同意后考虑再次保留生育功能治疗。
  • 再次治疗期间及治疗后需严密随访,关注再复发风险,再复发后可个体化选择全面分期手术或再次保留生育治疗。

局限性

  • 为回顾性研究,再治疗患者仅27例,样本量有限。
  • 复发患者来自9家医院中的4家,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the clinical efficacy and pregnancy outcomes of fertility- preserving re-treatment in patients with recurrent atypical endometrial hyperplasia (AEH) and early stage endometrial carcinoma (EEC) after achieved complete remission (CR) of primary fertility-preserving therapy. Methods: There were 104 cases of AEH and EEC collected from 9 hospitals in the multi-center research network platform of fertility-preserving therapy of endometrial carcinoma in China from January 2005 to May 2019. Thirth-one cases of them relapsed from four hospitals mentioned above,who achieved CR after primary fertility-preserving therapy,was analyzed retrospectively. Of the 31 cases, 27 cases chose fertility-preserving re-treatment. The demographic characteristics, re-treatment effect, clinical factors and pregnancy outcomes were observed. Results: (1) There were 16 AEH cases and 11 ECC cases among 27 recurrent patients who chose fertility-preserving therapy again. After re-treatment, CR was found in 13 out of 16 cases of AEH and 9 out of 11 cases of EEC. The overall CR rate was 81% (22/27). (2) After CR of recurrence, 5 cases (23%, 5/22) of re-recurrence were found after with a median time of 33 months (range 21-80 months). There were 4 cases underwent comprehensive surgical staging, and 1 patient chose the third round of fertility preservation therapy with fully informed consent, and CR was reached after 15 months. (3) There were 16 cases with pregnancy intention, with a total of 12 pregnancies, including 5 cases were natural pregnancy and 7 cases were assisted reproductive technology pregnancy. There were 5 live births. The follow-up time was up to May 2019, and the median follow-up time was 73 months (range 0-123 months). All 27 patients had disease free survival. Conclusions: Recurrent patients with AEH and EEC after achieving successful fertility-preserving therapy could choose fertility-preserving therapy again with comprehensive assessment and fully informed consent. After re-treatment, there is a certain tumor CR rate and pregnancy rate, while the close follow-up is required during treatment. 目的: 探讨子宫内膜非典型增生(AEH)及早期子宫内膜癌(EEC)经保留生育功能治疗达到完全缓解(CR),复发后再次保留生育功能治疗的临床疗效及妊娠结局。 方法: 收集2005年1月—2019年5月全国子宫内膜癌保留生育功能多中心研究网络平台中9家三级甲等医院收治的AEH和EEC患者共104例,整理其中经保留生育功能治疗达到CR后复发的31例患者(来自其中4家医院)的临床病理资料。31例复发患者中,再次接受保留生育功能治疗者27例,回顾性分析其复发后的病理类型、疗效、肿瘤结局及妊娠结局。 结果: (1)27例复发后再次保留生育功能治疗的患者中,AEH 16例、EEC 11例;再次保留生育功能治疗后22例达到CR(81%,22/27),其中AEH和EEC的CR率分别为13/16和9/11。(2)22例复发治疗后达CR的患者中,5例(23%,5/22)再复发,两次复发的中位间隔时间为33个月(21~80个月),其中4例行全面分期手术,1例在充分知情的情况下坚决选择第3轮保留生育功能治疗,15个月后达CR。(3)27例复发后再次保留功能治疗的患者中,有妊娠意愿者16例,共有12例妊娠,妊娠率为12/16。其中,5例为自然妊娠、7例为辅助生殖技术治疗后妊娠;5例足月妊娠,共分娩5例新生儿,活产率为5/12。随访截至2019年5月,中位随访时间为73个月(0~123个月),27例复发后再次接受保留生育功能治疗的患者均无瘤生存。 结论: 经保留生育功能治疗达到CR后复发的AEH和EEC患者,在全面评估病情和患者充分知情同意下,可以选择再次保留生育功能治疗;再次治疗仍具有一定的CR率和妊娠率,但治疗期间须严密观察。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. He YJ, Wang YQ, Tang HR, et al. [Clinical efficacy and pregnancy outcomes of fertility-preserving re-treatment after recurrence of the patient with atypical endometrial hyperplasia and early stage endometrial carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 2020. PMID: 32074769. doi:10.3760/cma.j.issn.0529-567X.2020.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。